Abstract
Straetemans and colleagues characterized αβT cells engineered to express a defined γδT cell receptor (TEG001) used in a first-in-human clinical study, with TLA in combination with NGS and qPCR. They provide a rapid strategy to evaluate the presence, integrity, and persistence of genetic information along the production chain of any GTMP.
Original language | English |
---|---|
Pages (from-to) | 561-571 |
Number of pages | 11 |
Journal | Molecular Therapy |
Volume | 28 |
Issue number | 2 |
Early online date | 14 Dec 2019 |
DOIs | |
Publication status | Published - 5 Feb 2020 |
Keywords
- engineered T cells
- gene therapy medicinal product
- GTMP
- targeted locus amplification
- TEG001
- TLA
- vector copy number
- γδT cells